Have your treatment recommendations for urothelial cancer patients changed given the ongoing COVID19 pandemic?

The therapeutic approach to cancer patients is changing rapidly due to the COVID-19 pandemic. In discussing with colleagues from several different countries, a few themes emerge.

Patient visits, surgery, and treatment that is not essential is being deferred. The benefit/risk that we each consider for individual patient decisions must now include risk of hospitalization and thus COVID-19 exposure in the risk assessment. How specific regimens including chemotherapy and IO impact risk of virus infe...

Excellent comments and answer by @Dr. First Last! Cancer is also a big threat to many patients. It is very hard to make hard & fast decisions in these situations; it is usually a case by case approach, balancing very carefully risks vs benefits, and discussing rationale, data, logistics, details of each option. Personally, I would still consider neoadjuvant cisplatin based chemotherapy in resectable MIBC considering level I evidence in fit patients, use strict precautions, and discuss in detail ...